CX11
Medium EvidenceCX11 is an investigational once-daily oral small-molecule GLP-1 receptor agonist (Corxel/Vincentage) that produced up to 11.5% weight loss at 36 weeks in a 246-patient U.S. Phase 2 obesity trial, with a notably low 12-16% vomiting rate and no hepatic safety signal; global Phase 3 is planned after positive China Phase 3 results.
What It Is
CX11 is an investigational once-daily oral small-molecule (non-peptide) GLP-1 receptor agonist being developed for obesity, overweight, and type 2 diabetes. It was discovered by Vincentage Pharma Co., Ltd. (China), with global ex-China rights acquired by Corxel Pharmaceuticals in December 2024. Like orforglipron, danuglipron, and aleniglipron, CX11 belongs to the emerging class of small-molecule GLP-1 agonists engineered to reproduce the appetite- and glucose-regulating effects of injectable incretin drugs (semaglutide, tirzepatide) in a scalable, room-temperature-stable pill that avoids cold-chain storage and once-weekly injections. On June 23, 2026, Corxel reported positive top-line results from a U.S. Phase 2 trial (NCT07011797) that enrolled 246 adults with obesity (BMI >= 30) or overweight (BMI 27 to <30 with at least one weight-related comorbidity), randomized 1:1:1:1:1 to CX11 120 mg, 160 mg, 200 mg (slow titration), 200 mg (fast titration), or placebo once daily for 36 weeks. CX11 met its primary endpoints, achieving up to 11.5% weight loss at 36 weeks with weight reduction continuing at a consistent rate and no evidence of a slowing (plateauing) trajectory - a pattern suggesting further loss with longer treatment. The tolerability profile was a headline feature: nausea occurred in 33-34% of participants, vomiting in just 12-16%, diarrhea in 4-12%, and constipation in 2-12%, with no severe GI events and GI adverse events concentrated during dose escalation before subsiding during maintenance. The overall discontinuation rate due to GI adverse events was low at 5.0%. Across more than 1,500 participants studied to date (including the China program), no hepatic safety signal has been identified - an important point given that hepatotoxicity concerns ended Pfizer's first oral GLP-1 candidate lotiglipron and complicated twice-daily danuglipron. The U.S. Phase 2 data were described as consistent with the competitive profile established in Vincentage's positive China Phase 3 obesity program. Corxel plans to advance CX11 into pivotal global Phase 3 studies in weight management, and is also developing CX12, an internally discovered oral small-molecule amylin receptor agonist, plus JX10, a thrombolytic for acute ischemic stroke.
Regulatory Status
U.S. Phase 2 trial (NCT07011797) met its primary endpoints in June 2026 with up to 11.5% weight loss at 36 weeks. Partner Vincentage previously reported positive China obesity Phase 3 results. Corxel plans to initiate pivotal global Phase 3 studies in weight management. Not approved for any indication.
Effective: June 2026
View FDA SourceWhy Researchers Study It
CX11 is part of the wave of oral non-peptide GLP-1 agonists that could dramatically widen access to incretin-based obesity therapy by removing the injection, cold-chain, and manufacturing-scale barriers of peptide drugs. Its Phase 2 profile is of particular interest because it pairs double-digit weight loss with a markedly low vomiting rate and a clean hepatic safety record across >1,500 participants - the two attributes (tolerability and liver safety) that have most often tripped up earlier oral GLP-1 candidates.
Proposed Mechanisms
- Small-molecule agonism of the GLP-1 receptor, reducing appetite and caloric intake
- Delays gastric emptying to promote satiety and reduce food intake
- Enhances glucose-dependent insulin secretion, supporting glycemic control
- Non-peptide structure allows once-daily oral dosing without the absorption enhancers or strict fasting requirements of peptide-based oral GLP-1s
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Phase 2 (U.S., NCT07011797) - randomized, double-blind, placebo-controlled | 246 adults with obesity (BMI >= 30) or overweight (BMI 27 to <30 + comorbidity) - 36 weeks, once-daily oral | Met primary endpoints: up to 11.5% weight loss at 36 weeks with no plateau; low GI burden (nausea 33-34%, vomiting 12-16%, diarrhea 4-12%, constipation 2-12%); 5.0% discontinuation due to GI AEs; no hepatic safety signal | Source |
| Phase 3 (China, Vincentage Pharma) | Adults with obesity/overweight - oral CX11 | Positive obesity Phase 3 results reported by partner Vincentage; described as establishing the competitive profile confirmed in the U.S. Phase 2 trial | Source |
Commonly Discussed Benefits
Researching CX11? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- Investigational - not approved for any indication; Phase 2 (U.S.) and Phase 3 (China) completed, global Phase 3 not yet started
- Top-line results only; full peer-reviewed data and detailed dose-response not yet published
- GI adverse events (nausea, vomiting, diarrhea, constipation) common, mainly during dose escalation
- China Phase 3 results reported by the partner rather than in a peer-reviewed journal at time of writing; cross-trial comparisons with orforglipron, aleniglipron, and oral semaglutide have significant limitations
- Long-term safety, durability of weight loss, and cardiovascular outcomes not yet established
Comparisons
See how CX11 compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Corxel Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Trial of CX11 in Obese and Overweight U.S. Adults - BioSpace (June 23, 2026) PubMed
- [2] Corxel to advance oral obesity drug to Phase III trials - Clinical Trials Arena (2026) PubMed
- [3] CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports - HCPLive (2026) PubMed
- [4] Corxel gears up for global pivotal push after oral GLP-1 posts 'competitive' phase 2 results - Fierce Biotech (2026) PubMed
Keep researching in the app
- Log CX11 to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Semaglutide
High EvidenceA GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.
Orforglipron
High EvidenceThe first oral non-peptide GLP-1 receptor agonist, FDA-approved in April 2026 for chronic weight management with no food or water restrictions.
Danuglipron
Medium EvidenceAn oral small-molecule GLP-1 receptor agonist discontinued by Pfizer in 2026 after a potential drug-induced liver injury signal, despite showing meaningful weight loss in Phase 2b.
Ecnoglutide
High EvidenceA cAMP signaling-biased GLP-1 receptor agonist approved in China for chronic weight management, with Phase 3 data showing up to 15.4% weight loss.
Aleniglipron
Medium EvidenceAn oral non-peptide small-molecule GLP-1 receptor agonist achieving 16.3% placebo-adjusted weight loss at 44 weeks in Phase 2 ACCESS II, with Phase 3 on track for Q3 2026 after positive FDA end-of-Phase 2 feedback.
Conveglipron
Low EvidenceAn oral, once-daily small-molecule GLP-1 receptor agonist (developmental code HDM1002) from Huadong Medicine, in clinical trials for obesity and type 2 diabetes — part of the next wave of GLP-1 'pills' competing with orforglipron.